Sparrow Pharmaceuticals

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for disorders of corticosteroid excess. It was founded to spare patients the ravages of steroids. Leveraging underappreciated scientific insights into corticosteroid biology, the company is working to provide better treatment options for serious disorders of hypercortisolism and to revolutionize the treatment of autoimmune and inflammatory conditions. Its lead product, SPI-62, is an oral, small molecule, a novel treatment designed to target the source of active intracellular corticosteroids in key tissues.

The company was founded in 2013 by David A. Katz and is based in Portland, Oregon, United States.

Sparrow Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Pharmaceutical, Biopharma, Therapeutics sector. The company focuses on Biotechnology and has secured $2.9B in funding across 48 round(s). With a team of 1-10 employees, Sparrow Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - Sparrow Pharmaceuticals, raised $10.2M. Discover more about their projects, partnerships, and impact on our platform.